Media.Player

Liposomal Clodronate as a Therapy for Autoimmune Hemolytic Anemia

技術優勢

The method is less invasive than surgery (splenectomy)Decrease use of steroidsDecrease side effects

技術應用

Therapy for autoimmune hemolytic anemiaThe therapy is applicable to both humans and companion animals

詳細技術說明

The efficacy of this therapy has been demonstrated by some strong in vivo data obtained in mice and dogs with AIHA.Using a mouse model in which animals were given anti red blood cell antibodies, treatment with liposomal clodronate substantially decreased red blood cell destruction.In addition, this effect was detected within hours and lasted at least a week.RBC clearance and the effects of LC treatment in dogs with AIHA. RBC clearance in 6 dogs with spontaneous AIHA was assessed by flow cytometry prior to treatment and again 24 hours after treatment with LC and the mean (┬▒ SE) percentage of labeled RBC present in circulation at each time point post infusion was determined. (B) RBC clearance kinetics were determined again 24 hours after treatment with 0.5 mL/kg LC. In 4 dogs (Nonresponders), there was no change in RBC clearance compared to clearance prior to treatment with LC, whereas in 2 dogs (Responders), RBC clearance was markedly reduced.

*Abstract

This invention is using liposomal clodronate as a therapy for autoimmune hemolytic anemia (AIHA).

*Principal Investigation

Name: John Kappler, Professor

Department: Integrated Department of Immunology

Name: Philippa Marrack, Professor

Department: Integrated Department of Immunology

國家/地區

美國